Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma.

Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R.

Mol Cancer Ther. 2018 Apr;17(4):849-857. doi: 10.1158/1535-7163.MCT-17-0868. Epub 2018 Feb 13.

2.

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK.

Mol Cancer Ther. 2017 Mar;16(3):428-439. doi: 10.1158/1535-7163.MCT-16-0496. Epub 2017 Feb 1.

Supplemental Content

Loading ...
Support Center